Likewise, Podar et al. demonstrated the effectiveness of the PKC-inhibitor enzastaurin in blocking the phorbol ester-induced activation of several PKC isoforms while concurrently disrupting the phosphorylation of downstream signaling molecules MARCKS and PKCμ in MM [131]. The gene discussed is MARCKS; the disease is Miyoshi myopathy.